These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8458108)

  • 21. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
    J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short- and long-term comparative study of anistreplase versus streptokinase in acute myocardial infarction.
    Silber H; Hausmann MJ; Katz A; Gilutz H; Zucker N; Ovsyshcher I
    Angiology; 1992 Jul; 43(7):572-7. PubMed ID: 1626735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction].
    López-Sendón JL
    Rev Esp Cardiol; 1992; 45 Suppl 2():9-20. PubMed ID: 1475514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolytic therapy for acute myocardial infarction. Are inclusion criteria too stringent?
    Handlin LR; Vacek JL
    Postgrad Med; 1994 Mar; 95(4):77-82. PubMed ID: 8121861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
    Naylor CD; Armstrong PW
    CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary artery thrombolysis: comparison of approved agents.
    Porter RS; DiPalma JR
    Am Fam Physician; 1991 Aug; 44(2):591-8. PubMed ID: 1907085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summary of U.S. clinical trials program for evaluation of anistreplase.
    Anderson JL
    Clin Cardiol; 1990 Mar; Suppl 5():V33-8; discussion V67-72. PubMed ID: 2182239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are the various thrombolytic agents equally effective in the treatment of acute transmural myocardial infarction?
    Claessens J; Haseldonckx C
    Jpn Heart J; 1992 Jul; 33(4):413-21. PubMed ID: 1453546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
    Lancet; 1990 Jul; 336(8707):71-5. PubMed ID: 1975322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolytic therapy in acute myocardial infarction.
    Paspa PA; Movahed A
    Am Fam Physician; 1992 Feb; 45(2):640-8. PubMed ID: 1739049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of perfusion data.
    Rapaport E
    Eur Heart J; 1990 Aug; 11 Suppl F():10-4. PubMed ID: 2121487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic therapy in Europe: current status.
    Vahanian A
    Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability of thrombolytic coronary reperfusion: an angiographic study of streptokinase and anistreplase.
    Sorensen SG; Hackworthy RA; Fitzpatrick PG; Menlove R; Anderson JL
    Clin Cardiol; 1990 Mar; Suppl 5():V15-9; discussion V27-32. PubMed ID: 2182235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What you should know about thrombolytic therapy for acute MI.
    Aragon D; Martin M
    Am J Nurs; 1993 Sep; 93(9):24-31; quiz 33. PubMed ID: 8213959
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
    Clin Trials Metaanal; 1993 Nov; 28(6):317-28. PubMed ID: 10150180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolytic therapy: then and now.
    Cole PL
    Heart Lung; 1991 Sep; 20(5 Pt 2):542-51. PubMed ID: 1910023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.